Cytokines impact natural killer cell phenotype and functionality against glioblastoma in vitro

被引:4
|
作者
Sivonen, Minna [1 ,2 ]
Sirvio, Katja A. [1 ]
Wojciechowski, Sara [1 ]
Kailaanmaki, Anssi [1 ]
Kaipainen, Satu [1 ]
Bailey, Aubrey [1 ]
Villalba, Martin [3 ,4 ]
Kekarainen, Tuija [1 ]
机构
[1] Kuopio Ctr Gene & Cell Therapy, Kuopio, Finland
[2] Univ Eastern Finland, AI Virtanen Inst, Biotechnol & Mol Med Unit, Kuopio, Finland
[3] Univ Montpellier, IRMB, INSERM, CNRS,CHU Montpellier, Montpellier, France
[4] Univ Eastern Finland, Fac Hlth Sci, AI Virtanen Inst Mol Sci, Kuopio, Finland
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
immunotherapy; natural killer cells; glioblastoma; cytokines; memory-like natural killer cells; HUMAN NK CELLS; T-CELLS; CLINICAL-GRADE; FEEDER-FREE; EXPANSION; ACTIVATION; MEMORY; CYTOTOXICITY; EXPRESSION; RECEPTOR;
D O I
10.3389/fimmu.2023.1227064
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Natural killer (NK) cells are a part of the innate immune system and first-line defense against cancer. Since they possess natural mechanisms to recognize and kill tumor cells, NK cells are considered as a potential option for an off-the-shelf allogeneic cell-based immunotherapy. Here, our objective was to identify the optimal cytokine-based, feeder-free, activation and expansion protocol for cytotoxic NK cells against glioblastoma in vitro.Methods: NK cells were enriched from human peripheral blood and expanded for 16 days with different activation and cytokine combinations. The expansion conditions were evaluated based on NK cell viability, functionality, expansion rate and purity. The cytotoxicity and degranulation of the expanded NK cells were measured in vitro from co-cultures with the glioma cell lines U-87 MG, U-87 MG EGFR vIII, LN-229, U-118 and DK-MG. The best expansion protocols were selected from ultimately 39 different conditions: three magnetic cell-selection steps (Depletion of CD3+ cells, enrichment of CD56+ cells, and depletion of CD3+ cells followed by enrichment of CD56+ cells); four activation protocols (continuous, pre-activation, re-activation, and boost); and four cytokine combinations (IL-2/15, IL-21/15, IL-27/18/15 and IL-12/18/15).Results: The expansion rates varied between 2-50-fold, depending on the donor and the expansion conditions. The best expansion rate and purity were gained with sequential selection (Depletion of CD3+ cells and enrichment of CD56+ cells) from the starting material and pre-activation with IL-12/18/15 cytokines, which are known to produce cytokine-induced memory-like NK cells. The cytotoxicity of these memory-like NK cells was enhanced with re-activation, diminishing the donor variation. The most cytotoxic NK cells were produced when cells were boosted at the end of the expansion with IL-12/18/15 or IL-21/15.Conclusion: According to our findings the ex vivo proliferation capacity and functionality of NK cells is affected by multiple factors, such as the donor, composition of starting material, cytokine combination and the activation protocol. The cytokines modified the NK cells' phenotype and functionality, which was evident in their reactivity against the glioma cell lines. To our knowledge, this is the first comprehensive comparative study performed to this extent, and these findings could be used for upscaling clinical NK cell manufacturing.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality
    Thessa Laeremans
    Sabine den Roover
    Cynthia Lungu
    Sigrid D’haese
    Rob A. Gruters
    Sabine D. Allard
    Joeri L. Aerts
    npj Vaccines, 8
  • [2] Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality
    Laeremans, Thessa
    den Roover, Sabine
    Lungu, Cynthia
    D'haese, Sigrid
    Gruters, Rob A. A.
    Allard, Sabine D. D.
    Aerts, Joeri L. L.
    NPJ VACCINES, 2023, 8 (01)
  • [3] Natural Killer Cell-Based Immunotherapy against Glioblastoma
    Morimoto, Takayuki
    Nakazawa, Tsutomu
    Maeoka, Ryosuke
    Nakagawa, Ichiro
    Tsujimura, Takahiro
    Matsuda, Ryosuke
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [4] Natural killer cell immunotherapy in glioblastoma
    Hosseinalizadeh, Hamed
    Roudkenar, Mehryar Habibi
    Roushandeh, Amaneh Mohammadi
    Kuwahara, Yoshikazu
    Tomita, Kazuo
    Sato, Tomoaki
    DISCOVER ONCOLOGY, 2022, 13 (01)
  • [5] Natural killer cell recognition of glioblastoma
    Close, H. J.
    Wurdak, H.
    Short, S. C.
    Melcher, A. A.
    Stead, L. F.
    Wilson, E. B.
    Cook, G. P.
    IMMUNOLOGY, 2014, 143 : 138 - 138
  • [6] Natural killer cell immunotherapy in glioblastoma
    Hamed Hosseinalizadeh
    Mehryar Habibi Roudkenar
    Amaneh Mohammadi Roushandeh
    Yoshikazu Kuwahara
    Kazuo Tomita
    Tomoaki Sato
    Discover Oncology, 13
  • [7] Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme
    Cooksey, Luke C.
    Friesen, Derek C.
    Mangan, Enrique D.
    Mathew, Porunelloor A.
    CELLS, 2024, 13 (18)
  • [8] Natural Killer Cell Phenotype and Functionality Affected by Exposure to Extracellular Survivin and Lymphoma-Derived Exosomes
    Ferguson Bennit, Heather R.
    Gonda, Amber
    Kabagwira, Janviere
    Oppegard, Laura
    Chi, David
    Licero Campbell, Jenniffer
    De Leon, Marino
    Wall, Nathan R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (03) : 1 - 18
  • [9] Natural killer cell awakening: unleash cancer-immunity cycle against glioblastoma
    Minjie Wang
    Zijie Zhou
    Xuan Wang
    Chaocai Zhang
    Xiaobing Jiang
    Cell Death & Disease, 13
  • [10] Unlocking Glioblastoma Secrets: Natural Killer Cell Therapy against Cancer Stem Cells
    Du, Yuanning
    Pollok, Karen E.
    Shen, Jia
    CANCERS, 2023, 15 (24)